Allworth Financial LP Has $256,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Allworth Financial LP boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 462 shares of the company’s stock after acquiring an additional 25 shares during the quarter. Allworth Financial LP’s holdings in IDEXX Laboratories were worth $256,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IDXX. Moneta Group Investment Advisors LLC increased its stake in shares of IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after buying an additional 7,441,162 shares in the last quarter. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $336,416,000. International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories by 51,631.3% in the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after buying an additional 546,775 shares in the last quarter. Morgan Stanley increased its stake in shares of IDEXX Laboratories by 36.0% in the fourth quarter. Morgan Stanley now owns 986,232 shares of the company’s stock valued at $402,344,000 after buying an additional 260,926 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of IDEXX Laboratories by 6.4% in the second quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after buying an additional 214,529 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock valued at $24,871,960 over the last 90 days. 2.18% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on IDXX shares. The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Barclays raised their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a report on Tuesday, January 30th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $504.14 on Thursday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a market cap of $41.87 billion, a P/E ratio of 50.06, a price-to-earnings-growth ratio of 2.82 and a beta of 1.26. The stock’s 50-day moving average price is $547.97 and its two-hundred day moving average price is $506.75.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 earnings per share. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.